Literature DB >> 10417944

Serotonin syndrome caused by overdose with paroxetine and moclobemide.

C R FitzSimmons1, S Metha.   

Abstract

Well known clinical syndromes can be produced by overdose with more commonly ingested substances such as opiates or tricyclic antidepressants. A case of a much more unusual syndrome presenting to the accident and emergency department resulting from overdose with a combination of tablets is reported. The clinical presentation of serotonin syndrome and its management are described. This resulted from acute ingestion of paroxetine, a selective serotonin reuptake inhibitor, and moclobemide, a monoamine oxidase inhibitor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417944      PMCID: PMC1343379          DOI: 10.1136/emj.16.4.293

Source DB:  PubMed          Journal:  J Accid Emerg Med        ISSN: 1351-0622


  10 in total

1.  Report of a fluoxetine fatality.

Authors:  R L Kincaid; M M McMullin; S B Crookham; F Rieders
Journal:  J Anal Toxicol       Date:  1990 Sep-Oct       Impact factor: 3.367

Review 2.  The serotonin syndrome.

Authors:  H Sternbach
Journal:  Am J Psychiatry       Date:  1991-06       Impact factor: 18.112

3.  An uncommon fatality due to moclobemide and paroxetine.

Authors:  P P Singer; G R Jones
Journal:  J Anal Toxicol       Date:  1997-10       Impact factor: 3.367

Review 4.  Selective serotonin reuptake inhibitors. Pharmacology and clinical implications in anaesthesia and critical care medicine.

Authors:  P C Kam; G W Chang
Journal:  Anaesthesia       Date:  1997-10       Impact factor: 6.955

5.  Serotonin syndrome caused by a moclobemide-clomipramine interaction.

Authors:  O Spigset; T Mjörndal; O Lövheim
Journal:  BMJ       Date:  1993-01-23

6.  Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses.

Authors:  P J Neuvonen; S Pohjola-Sintonen; U Tacke; E Vuori
Journal:  Lancet       Date:  1993-12-04       Impact factor: 79.321

Review 7.  Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.

Authors:  P R Finley
Journal:  Ann Pharmacother       Date:  1994-12       Impact factor: 3.154

Review 8.  Fluoxetine.

Authors:  L Gram
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

Review 9.  The serotonin syndrome. Implicated drugs, pathophysiology and management.

Authors:  K A Sporer
Journal:  Drug Saf       Date:  1995-08       Impact factor: 5.606

Review 10.  Fluoxetine overdose: a case report.

Authors:  T P Rohrig; R W Prouty
Journal:  J Anal Toxicol       Date:  1989 Sep-Oct       Impact factor: 3.367

  10 in total
  4 in total

Review 1.  Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

Authors:  Jacob P R Jacobsen; Andrew D Krystal; K Ranga R Krishnan; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2016-09-28       Impact factor: 14.819

2.  Paroxetine overdose.

Authors:  Arun K Gupta; Pankaj Verma; Samir K Praharaj; Dipayan Roy; Anuradha Singh
Journal:  Indian J Psychiatry       Date:  2005-07       Impact factor: 1.759

Review 3.  What to do if an initial antidepressant fails?

Authors:  Roger S McIntyre; Aleksandra Müller; Deborah A Mancini; Eric S Silver
Journal:  Can Fam Physician       Date:  2003-04       Impact factor: 3.275

4.  Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity.

Authors:  Geoffrey K Isbister; L P Hackett; Andrew H Dawson; Ian M Whyte; Anthony J Smith
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.